Compositions comprising cannabinoid ions that are dissolved in glycerol
Various aspects of this patent document relate to cannabinoid ions that are dissolved in glycerol, in which the cannabinoid ions are not carboxylates.
1. A composition, comprising a liquid phase that comprises a solute and a solvent, wherein the solute is a cannabinoid ion; the cannabinoid ion is 3-(3,7-dimethylocta-2,6-diene-1-yl)-6-pentyl-1,2-benzoquinone-4-oxide; the solvent is glycerol; and the cannabinoid ion is dissolved in the glycerol.
2. The composition of claim 1 , comprising the glycerol at a concentration of at least 50 percent by weight.
3. The composition of claim 1 , comprising ethanol.
4. The composition of claim 1 , comprising water.
5. The composition of claim 1 , comprising a metal cation.
6. The composition of claim 5 , wherein the metal cation is sodium cation (“Na+”).
7. The composition of claim 5 , wherein the metal cation is potassium cation (“K+”).
8. The composition of claim 5 , comprising the metal cation and the cannabinoid ion at a molar ratio of at least 1:1 and no greater than 5:4.
9. The composition of claim 1 , comprising a concentration of the cannabinoid ion that is dissolved in the glycerol, wherein the cannabinoid ion has a conjugate acid that has a solubility in the liquid phase that is less than the concentration of the cannabinoid ion that is dissolved in the glycerol.
10. The composition of claim 1 , comprising a molecule and the cannabinoid ion at a molar ratio of at least 1:1,000,000 and less than 1:1, wherein the cannabinoid ion has a conjugate acid; and the molecule is the conjugate acid of the cannabinoid ion.
11. The composition of claim 1 , comprising the cannabinoid ion at a concentration of at least 1 gram per liter.
12. The composition of claim 1 , wherein the composition is formulated for oral administration to a human or an animal.
13. The composition of claim 1 , wherein the composition is formulated for topical administration to a human or an animal.
14. A medicament, comprising a composition according to claim 1 .
15. A method to administer a composition to a subject, comprising orally administering a composition according to claim 1 to the subject, wherein the subject is a human or an animal.
16. A method to administer a composition to a subject, comprising topically administering a composition according to claim 1 to the subject, wherein the subject is a human or an animal.
17. A composition, comprising a liquid phase that comprises a solute and a solvent, wherein the solute is a cannabinoid ion; the cannabinoid ion is 2-(3,7-dimethylocta-2,6-diene-1-yl)-3-hydroxy-5-pentylbenzene-1-oxide; the solvent is glycerol; and the cannabinoid ion is dissolved in the glycerol.
18. A method to administer a composition to a subject, comprising topically administering a composition according to claim 17 to the subject, wherein the subject is a human.
19. A composition, comprising a liquid phase that comprises a solute and a solvent, wherein the solute is a cannabinoid ion; the cannabinoid ion is 2-(3,7-dimethylocta-2,6-diene-1-yl)-5-pentyl-1,4-benzoquinone-3-oxide; the solvent is glycerol; and the cannabinoid ion is dissolved in the glycerol.
20. A method to administer a composition to a subject, comprising topically administering a composition according to claim 19 to the subject, wherein the subject is a human.